Evogene Ltd. (EVGN)

NASDAQ: EVGN · IEX Real-Time Price · USD
+0.037 (5.28%)
At close: Dec 4, 2023, 3:59 PM
+0.012 (1.70%)
After-hours: Dec 4, 2023, 4:01 PM EST

Company Description

Evogene Ltd., together with its subsidiaries, operates as a computational biology company.

It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform.

The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.

Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms.

The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses.

The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally.

The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.

Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Evogene Ltd.
Evogene logo
Country Israel
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 137
CEO Ofer Haviv CPA

Contact Details

13 Gad Feinstein Street, Park Rehovot P.o.b 2100
Rehovot, L3 76121
Phone 97289311900
Website evogene.com

Stock Details

Ticker Symbol EVGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574565
CUSIP Number M4119S104
ISIN Number IL0011050551
SIC Code 2870

Key Executives

Name Position
Ofer Haviv CPA Chief Executive Officer and Pres
Mark Kapel Chief Technology Officer
Dr. Elran Hillel Haber M.B.A., Ph.D. Chief Executive Officer of Biomica Ltd
Yaron Eldad Chief Financial Officer
Dr. Eyal Emmanuel Chief Scientific Officer
Sassi Masliah Executive Vice President of Corporate Development
Liat Foigel Wejgman Vice President of Human Resources
Dr. Nir Arbel Chief Product Officer
Dotan Borenstein Chief Business Officer of Lavie Bio Ltd.
Eyal Ronen Executive Vice President of Business Development

Latest SEC Filings

Date Type Title
Nov 15, 2023 6-K Report of foreign issuer
Nov 8, 2023 6-K Report of foreign issuer
Sep 21, 2023 6-K Report of foreign issuer
Sep 19, 2023 6-K Report of foreign issuer
Sep 13, 2023 6-K Report of foreign issuer
Aug 23, 2023 6-K Report of foreign issuer
Aug 17, 2023 6-K Report of foreign issuer
Aug 8, 2023 6-K Report of foreign issuer
Jul 18, 2023 424B5 Filing
Jul 17, 2023 6-K Report of foreign issuer